MoneyWorks4Me

Eris Lifesciences - Quaterly Results

30 Jul 2026 Evaluate
The sales for the June 2026 quarter moved down to Rs. 4439.90 millions as compared to Rs. 5786.40 millions during the year-ago period.A big decline of -51.70% was reported for the quarter ended June 2026 to Rs. 483.00  millions from Rs. 999.90 millions of corresponding previous quarter.The company reported a degrowth in operating Profit to 1462.80 millions from 2390.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 4439.90 5786.40 -23.27 4439.90 5786.40 -23.27 18217.40 16977.50 7.30
Other Income 263.80 226.80 16.31 263.80 226.80 16.31 983.10 355.10 176.85
PBIDT 1462.80 2390.00 -38.79 1462.80 2390.00 -38.79 7106.40 5220.60 36.12
Interest 421.60 451.40 -6.60 421.60 451.40 -6.60 1795.40 2202.40 -18.48
PBDT 1041.20 1938.60 -46.29 1041.20 1938.60 -46.29 5164.30 3018.20 71.11
Depreciation 399.80 376.00 6.33 399.80 376.00 6.33 1543.80 1817.70 -15.07
PBT 641.40 1562.60 -58.95 641.40 1562.60 -58.95 3620.50 1200.50 201.58
TAX 158.40 562.70 -71.85 158.40 562.70 -71.85 1180.00 426.60 176.61
Deferred Tax 56.10 291.00 -80.72 56.10 291.00 -80.72 570.40 206.80 175.82
PAT 483.00 999.90 -51.70 483.00 999.90 -51.70 2440.50 773.90 215.35
Equity 138.60 136.20 1.76 138.60 136.20 1.76 138.50 136.20 1.69
PBIDTM(%) 32.95 41.30 -20.23 32.95 41.30 -20.23 39.01 30.75 26.86

Eris Lifesciences Share Price

1403.00 10.45 (0.75%)
11-Aug-2026 12:55 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1932.75
Dr. Reddys Labs. 1194.00
Cipla 1463.10
Lupin 2268.20
Zydus Lifesciences 1158.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: